Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Eurofins Scientific SE's current 5-Year Share Buyback Ratio was 1.30%.
XTER:ESF0's 5-Year Share Buyback Ratio is ranked better than 93.75% of 176
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.3
vs XTER:ESF0: 1.30
Eurofins Scientific SE (XTER:ESF0) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Eurofins Scientific SE 5-Year Share Buyback Ratio Related Terms
XTER:ESF0 vs TMO, DHR, NTRA: 5-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE 5-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's 5-Year Share Buyback Ratio falls into.
Eurofins Scientific SE 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of 1.30 mean?
Eurofins Scientific SE (XTER:ESF0) has a 5-Year Share Buyback Ratio of 1.30 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Eurofins Scientific SE and its competitors. According to the industry distribution chart, Eurofins Scientific SE ranks #11 out of 176 companies in the Medical Diagnostics & Research industry, placing it in the top 6.2%.
Is Eurofins Scientific SE's 5-Year Share Buyback Ratio too high?
Eurofins Scientific SE's current 5-Year Share Buyback Ratio is 1.30. Based on the distribution chart, Eurofins Scientific SE ranks #11 out of 176 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Eurofins Scientific SE has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's 5-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #11 out of 176 companies for 5-Year Share Buyback Ratio. This places Eurofins Scientific SE in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 5-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Eurofins Scientific SE and its competitors. Eurofins Scientific SE's current 5-Year Share Buyback Ratio is 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (XTER:ESF0) is currently considered Modestly Overvalued. The stock's GF Value™ is €66.50, compared to a current price of €78.36 — trading 17.8% above its estimated fair value. The current 5-Year Share Buyback Ratio is 1.30. Eurofins Scientific SE's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (XTER:ESF0), the current 5-Year Share Buyback Ratio is 1.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (XTER:ESF0) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of €78.36 is trading 17.8% above its estimated GF Value™ of €66.50.
GuruFocus considers Eurofins Scientific SE to be Modestly Overvalued.
Key valuation signals for XTER:ESF0:
5-Year Share Buyback Ratio: 1.30
GF Value™: €66.50 vs. price of €78.36 (17.8% above fair value)
No single metric tells the full story. See the XTER:ESF0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins Scientific SE is a Luxembourg-based laboratory testing company operating a decentralized network of laboratories and service companies worldwide. It provides analytical testing and laboratory services across several segments: food, feed, and environmental testing; biopharmaceutical services, including contract research and bioanalytical testing; diagnostic services and products for clinical and medical applications; and consumer product and technology testing. Its tests assess the safety, identity, composition, authenticity, purity, origin, and traceability of biological substances and products. Customers include food producers, pharmaceutical and biotechnology companies, healthcare providers, government agencies, and consumer goods manufacturers. Eurofins operates a large network of laboratories and sites across Europe, North America, and the rest of the world, with Europe and North America representing the largest revenue regions. Revenue is generated primarily through fee-for-service testing contracts, diagnostic testing, and related laboratory services.
79GF Score
Get the complete analysis for XTER:ESF0
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:ESF0 has been successfully added to your 
